
Opinion|Videos|December 5, 2024
Treatment Switches and the Future of Hidradenitis Suppurativa Management
Author(s)Jennifer Hsiao, MD, Rani Cooper, MD
Key Takeaways
Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5





















